CD4 and cancer: In contrast, IHC for effector immune cells revealed that ACT with SRC-3 KO Tregs significantly increased the number of CD4+ T cells, CD8+ T cells, and NK cells in cancers compared to ACT with wild-type Tregs (Fig. 5 E–G and SI Appendix, Fig. S14 B–D).